• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Statements

DNDi contribution to the World Health Organization roadmap on access to medicines and vaccines 2019-2023

Geneva, Switzerland — 10 Sep 2018

Intervention of Dr Bernard Pécoul, MD, MPH, Executive Director, Drugs for Neglected Diseases initiative

Chair, distinguished colleagues,

DNDi welcomes the development of a roadmap to tackle access to and shortages of medicines. Today the consequences of lack of access to existing and new health tools are felt in all countries, at all levels of income, and across diseases areas, from insufficient R&D for neglected and emerging infectious diseases, AMR, and high prices of medicines, such as for Hepatitis C or oncology.

If this access crisis is to be resolved, the roadmap must include concrete deliverables in the short-, medium-, and long-term, that provide practical guidance and support to all the stakeholders involved.

Our experience over the last 15 years has shown that it is possible to work openly and collaboratively with a variety of partners to develop affordable and easy-to-use drugs provided there is a shared vision, clear definition of needs, target product profiles, careful coordination of partners, and policies to ensure sustainable, equitable access.

We would like to make the following proposals for some tangible deliverables:

  1. Prioritization of R&D: priority setting based on public health needs, not commercial gain is crucial, The WHO has a key role in providing guidance through:
    • The reconvening of the Expert Committee on Health Research and Development to identify health R&D priorities. The WHO could then produce a list of missing essential medicines.
    • The formulation of a methodology for the prioritization of R%&D needs, including through the use of TPPs.
  2. Open and collaborative approaches to innovation can significantly speed up drug discovery, increase efficiency and reduce costs. The roadmap should include:
    • A review and evaluation of existing models, and of best practices.
    • The development of a Code of Principles for Biomedical R&D, based on the practical implementation of the CEWG principles of affordability, effectiveness, efficiency and equity to provide guidance to all R&D actors.
    • The development of a pro-access legal terms repository, that promotes access to knowledge throughout the R&D process, and reflects the flexibilities provided for in the TRIPS Agreement.
    • Support to Member States to implement existing schemes which delink R&D costs from product prices and volume.
    • A specific commitment to help mobilize financial resources to ensure that plans can be turned into action.
  3. Regulatory infrastructure
    • A review and identification of continued gaps in regulatory capacity, and harmonization of regional regulatory authorities, to continue to build capacity where needed.
  4. Finally, there are two gaps in the implementation plan:
    • first, no mention is made of the importance of diagnostics, which are critical in facilitating access, and rational use, which is key to sustainable access;
    • second, the roadmap should include recognition of the specific needs of children, who are among the most neglected.

For our part, we will continue to contribute to the WHO efforts to achieve access for all people, everywhere.

Read about the development of the roadmap on access to medicines and vaccines 2019-2023

Policy advocacy

Read, watch, share

Loading...
Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Statements
19 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

VIEW ALL

Speak out

Please help us raise awareness by sharing this story.

Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License